Ratings CureVac N.V.

Equities

CVAC

NL0015436031

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2025-06-13 pm EDT			5-day change	1st Jan Change
5.570 ^USD	-0.54%		+26.30%	+63.34%

Jun. 13	Jefferies Downgrades CureVac to Hold From Buy, $5 Price Target	MT
Jun. 13	CUREVAC : Downgraded to Neutral by Jefferies	ZD

Summary: CureVac N.V.

On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
From a short-term investment perspective, the company presents a deteriorated fundamental situation
The company has a poor ESG score according to MSCI, which ranks companies by sector.

Highlights: CureVac N.V.

Thanks to a sound financial situation, the firm has significant leeway for investment.

Weaknesses: CureVac N.V.

According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
The company's earnings growth outlook lacks momentum and is a weakness.
As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
Low profitability weakens the company.
The company's "enterprise value to sales" ratio is among the highest in the world.
For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
Over the past four months, analysts' average price target has been revised downwards significantly.
The overall consensus opinion of analysts has deteriorated sharply over the past four months.
Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
The company's earnings releases usually do not meet expectations.

Ratings Chart: CureVac N.V.

Source: Surperformance

ESG chart: CureVac N.V.

Source: MSCI

Sector Comparison:

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Fundamentals (Composite)	Global Valuation (Composite)	Capi.($)
CUREVAC N.V.	-	-	1.25B
LONZA GROUP AG			49.5B
IQVIA HOLDINGS INC.			27.14B
CELLTRION, INC.			26.06B
EUROFINS SCIENTIFIC SE			12.53B
ICON PUBLIC LIMITED COMPANY			11.57B
QIAGEN N.V.			10.2B
Average			19.75B
Weighted average by Cap.

See all sector ratings

Investor (Composite)

Trader (Composite)

ESG MSCI

BBB

Financials

Revenue growth

EPS growth

Capital Efficiency (Composite)

Net Margin

Financial Health (Composite)

Valuation

P/E

EV/Revenue

EV/EBITDA

PBR

Dividend Yield

Revisions

Revenue revisions (1 year)

Revenue revisions (4 months)

Revenue revisions (1 month)

EPS revisions (1 year)

EPS revisions (4 months)

Consensus

Analysts' buy/sell recommendations

Analysts' recommendations evolution (4 months)

Analysts' target price

Analysts' target price evolution (4 months)

Analysts' target price evolution (1 year)

Business Predictability

Surprise rates

Analysts' coverage

Analysts' recommendations divergence

Analysts' Target price divergence

Financial estimates divergence

ESG

ESG: Environment

ESG: Social

ESG: Governance

ESG: Controversy

ESG: Ethical controversies

ESG: Human rights controversies

ESG: Tax subsidies controversies

ESG: Sharia compliant

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes